Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication.

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother (2016) 0.76

A role for STEAP2 in prostate cancer progression. Clin Exp Metastasis (2014) 0.75

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64

Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J Oral Pathol Med (2012) 1.56

Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res (2005) 1.55

SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest (2011) 1.52

An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res (2002) 1.45

Polymorphism of Clara cell 10-kD protein gene of sarcoidosis. Am J Respir Crit Care Med (2003) 1.40

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31

A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma. Am J Surg Pathol (2014) 1.30

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother (2010) 1.25

PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res (2007) 1.21

Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol (2007) 1.18

Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol (2011) 1.18

Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol (2007) 1.17

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med (2004) 1.17

Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol (2005) 1.16

HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci (2007) 1.16

Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol (2002) 1.14

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res (2005) 1.10

Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci (2008) 1.10

Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother (2009) 1.10

Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci (2006) 1.10

Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS One (2013) 1.09

Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol (2008) 1.09

HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res (2012) 1.09

NK/T-cell lymphoma of bilateral adrenal glands in a patient with pyothorax. Diagn Pathol (2012) 1.09

Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy (2010) 1.07

Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med (2005) 1.06

Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci (2008) 1.04

Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene (2004) 1.04

Molecular pathological approaches to human tumor immunology. Pathol Int (2009) 1.04

ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One (2013) 1.03

Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int (2012) 1.02

Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci (2012) 1.02

The functioning antigens: beyond just as the immunological targets. Cancer Sci (2009) 1.01

Clinical assessment of the relationship between the third molar and the inferior alveolar canal using panoramic images and computed tomography. J Oral Maxillofac Surg (2008) 1.00